[go: up one dir, main page]

EE04481B1 - Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks - Google Patents

Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks

Info

Publication number
EE04481B1
EE04481B1 EE9800255A EE9800255A EE04481B1 EE 04481 B1 EE04481 B1 EE 04481B1 EE 9800255 A EE9800255 A EE 9800255A EE 9800255 A EE9800255 A EE 9800255A EE 04481 B1 EE04481 B1 EE 04481B1
Authority
EE
Estonia
Prior art keywords
peptide
pharmaceutical composition
immune modulation
based pharmaceutical
adjuvant based
Prior art date
Application number
EE9800255A
Other languages
English (en)
Other versions
EE9800255A (et
Inventor
Schmidt Walter
L. Birnstiel Max
Steinlein Peter
Buschle Michael
Schweighoffer Tam�s
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27215945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04481(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of EE9800255A publication Critical patent/EE9800255A/et
Publication of EE04481B1 publication Critical patent/EE04481B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EE9800255A 1996-02-24 1997-02-21 Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks EE04481B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (2)

Publication Number Publication Date
EE9800255A EE9800255A (et) 1999-02-15
EE04481B1 true EE04481B1 (et) 2005-06-15

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800255A EE04481B1 (et) 1996-02-24 1997-02-21 Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks

Country Status (34)

Country Link
US (1) US7105162B1 (et)
EP (1) EP0881906B2 (et)
JP (1) JP4184433B2 (et)
KR (1) KR100457647B1 (et)
CN (1) CN1177610C (et)
AR (1) AR005945A1 (et)
AT (1) ATE274350T1 (et)
AU (1) AU722264B2 (et)
BG (1) BG63682B1 (et)
BR (1) BR9707694A (et)
CA (1) CA2243559C (et)
CO (1) CO4600681A1 (et)
CZ (1) CZ295396B6 (et)
DE (1) DE59711873D1 (et)
DK (1) DK0881906T4 (et)
EE (1) EE04481B1 (et)
ES (1) ES2225951T5 (et)
HR (1) HRP970100B1 (et)
HU (1) HU224410B1 (et)
ID (1) ID16038A (et)
IL (1) IL125361A (et)
MY (1) MY119276A (et)
NO (1) NO983850L (et)
NZ (1) NZ332020A (et)
PE (1) PE55398A1 (et)
PL (1) PL189413B1 (et)
PT (1) PT881906E (et)
RO (1) RO119344B1 (et)
RS (1) RS50101B (et)
SI (1) SI0881906T2 (et)
SK (1) SK284582B6 (et)
TR (1) TR199801649T2 (et)
TW (1) TW585774B (et)
WO (1) WO1997030721A1 (et)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE69936355T2 (de) * 1998-02-25 2008-02-21 The Government Of The United States, As Represented By The Secretary Of The Army Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der transkutanen Immunantwort
CA2325818C (en) * 1998-04-20 2008-09-02 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
WO2000048630A1 (en) * 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
AU2003258672B2 (en) 2002-09-13 2008-10-30 Intercell Ag Method for isolating hepatitis C virus peptides
CN1705679B (zh) 2002-10-15 2011-04-06 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
CN102512670A (zh) 2003-03-04 2012-06-27 英特塞尔股份公司 化脓链球菌抗原
EP2345420B1 (en) 2003-03-24 2016-01-06 Valneva Austria GmbH Use of a TH1 immune response inducing adjuvant for enhancing immune responses
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
AU2004230244B2 (en) 2003-04-15 2011-09-22 Intercell Ag S. pneumoniae antigens
JP2007535894A (ja) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・アガラクティエ抗原ｉ＋ｉｉ
CN102304527A (zh) 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
EP1648502B1 (en) 2003-07-11 2010-12-01 Intercell AG Hcv vaccines
ATE381945T1 (de) 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
US9573979B2 (en) 2004-09-24 2017-02-21 Susanne Modrow Modified VP1-capsid protein of parvovirus B19
CN101048172A (zh) * 2004-10-29 2007-10-03 英特塞尔股份公司 用于慢性hcv患者的hcv疫苗
EP1872793B1 (en) * 2005-04-20 2012-10-10 Mitsuru Akashi Polyamino acid for use as adjuvant
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
EP2287176A1 (en) 2006-09-15 2011-02-23 Intercell AG Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
EP2338902A1 (en) 2007-05-02 2011-06-29 Intercell AG Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
CA2690271A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
CN101795709B (zh) 2007-08-02 2013-07-17 彼昂德瓦克斯医药有限公司 多亚基多表位流感疫苗
WO2009120378A2 (en) * 2008-03-27 2009-10-01 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
CN102239253A (zh) 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 谷氨酰tRNA合成酶（GtS）片段
US8617574B2 (en) 2009-02-13 2013-12-31 Valneva Austria Gmbh Nontypable Haemophilus influenzae antigens
WO2011024071A1 (en) * 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
CA2780274C (en) 2009-11-09 2018-06-26 Spotlight Technology Partners Llc Fragmented hydrogels
AU2010314992B2 (en) 2009-11-09 2016-09-15 Spotlight Technology Partners Llc Polysaccharide based hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
BR112017006969A2 (pt) 2014-10-07 2017-12-19 Cytlimic Inc peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
US10568948B2 (en) 2015-05-13 2020-02-25 Agenus Inc. Vaccines for treatment and prevention of cancer
US20200138939A1 (en) * 2015-12-16 2020-05-07 Huvet Bio, Inc. Vaccine adjuvant composition based on amphiphilic polyamino acid polymer, containing squalene
US12065699B2 (en) 2016-03-15 2024-08-20 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
EP3463440A4 (en) * 2016-05-27 2020-04-15 Etubics Corporation NEO-EPITOPE-BASED VACCINE COMPOSITIONS AND METHODS OF USE
ES2972560T3 (es) 2016-10-11 2024-06-13 Nec Corp Medicamento que comprende un agonista de receptores tipo Toll, proteína LAG-3, un péptido derivado de HSP70 y un péptido derivado de GPC3
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (et) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
BE1000587A4 (fr) * 1986-06-13 1989-02-14 Oncogen Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
GB2220939B (en) * 1988-06-10 1992-02-26 Medical Res Council Peptide fragments of hiv and their use in vaccines and diagnosis
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
US5480967A (en) 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP0636028B1 (en) 1992-04-03 2004-03-03 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising an amphiphatic cationic peptide
DE69333670T2 (de) 1992-08-31 2005-03-10 Ludwig Institute For Cancer Research Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ281462B6 (cs) * 1993-07-12 1996-10-16 Aliatros Medical, A.S. Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju

Also Published As

Publication number Publication date
ID16038A (id) 1997-08-28
MY119276A (en) 2005-04-30
EE9800255A (et) 1999-02-15
JP4184433B2 (ja) 2008-11-19
AR005945A1 (es) 1999-07-21
ATE274350T1 (de) 2004-09-15
BG102714A (en) 1999-06-30
NZ332020A (en) 2000-02-28
EP0881906B1 (de) 2004-08-25
SK114598A3 (en) 1999-06-11
RO119344B1 (ro) 2004-08-30
RS50101B (sr) 2009-01-22
BG63682B1 (bg) 2002-09-30
HK1017257A1 (en) 1999-11-19
ES2225951T5 (es) 2009-06-15
SI0881906T2 (sl) 2009-06-30
DE59711873D1 (de) 2004-09-30
IL125361A0 (en) 1999-03-12
ES2225951T3 (es) 2005-03-16
JP2000506125A (ja) 2000-05-23
SI0881906T1 (en) 2004-12-31
EP0881906A1 (de) 1998-12-09
CZ268998A3 (cs) 1999-07-14
KR19990082601A (ko) 1999-11-25
YU6297A (sh) 1999-09-27
BR9707694A (pt) 1999-07-27
SK284582B6 (sk) 2005-07-01
HUP9901186A2 (hu) 1999-07-28
TW585774B (en) 2004-05-01
PL189413B1 (pl) 2005-08-31
PE55398A1 (es) 1998-09-22
CA2243559C (en) 2011-08-09
DK0881906T4 (da) 2009-05-25
HU224410B1 (hu) 2005-08-29
CO4600681A1 (es) 1998-05-08
KR100457647B1 (ko) 2005-06-20
AU722264B2 (en) 2000-07-27
NO983850D0 (no) 1998-08-21
HUP9901186A3 (en) 2001-01-29
HRP970100A2 (en) 1998-04-30
EP0881906B2 (de) 2009-02-04
CA2243559A1 (en) 1997-08-28
HRP970100B1 (en) 2001-04-30
CN1177610C (zh) 2004-12-01
TR199801649T2 (xx) 1998-12-21
NO983850L (no) 1998-10-21
CZ295396B6 (cs) 2005-08-17
PT881906E (pt) 2004-10-29
PL328455A1 (en) 1999-02-01
DK0881906T3 (da) 2004-12-20
CN1211926A (zh) 1999-03-24
AU1875997A (en) 1997-09-10
US7105162B1 (en) 2006-09-12
WO1997030721A1 (de) 1997-08-28
IL125361A (en) 2002-08-14

Similar Documents

Publication Publication Date Title
EE04481B1 (et) Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks
HUP9904177A3 (en) Antibody against human parathormone related peptides
FI961350L (fi) Hapteenimerkityt peptidit
ID17860A (id) Komposisi vaksin
NO985680D0 (no) Peptidderivater
NO983849L (no) Peptidderivater
EE04001B1 (et) Peptiidne farmatseutiline kompositsioon
FI970168A7 (fi) Peptidejä
FI963334L (fi) Tyrosinaasista peräisin olevat eristetyt peptidit ja niiden käyttö
EE03857B1 (et) Ravimkoostised külmkuivatamiseks
LV12250A (lv) Farmaceitiskas kompozicijas uz diklofenaka bazes
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
FI964363L (fi) Peptidejä
FI971427L (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
ID18698A (id) Komposisi farmasi
GB2331521B (en) Vaccine preparations
ITMI962628A0 (it) Composizione farmaceutica
AU4489896A (en) Avian recombinant live vaccine
IL116976A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
SG54113A1 (en) Novel peptide a method for its preparation and a pharmaceutical composition containing the peptide
ZA96741B (en) Peptide a method for its preparation and a pharmaceutical composition containing the peptide
ITMI922675A1 (it) Peptidi immunogenici
SE9601854D0 (sv) Farmaceutisk komposition
SE9604299D0 (sv) Pharmaceutical composition

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231